Regeneron

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Regeneron 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About REGN

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. 

CEO
Leonard S. Schleifer
CEOLeonard S. Schleifer
Employees
15,106
Employees15,106
Headquarters
Tarrytown, New York
HeadquartersTarrytown, New York
Founded
1988
Founded1988
Employees
15,106
Employees15,106

REGN Key Statistics

Market cap
61.99B
Market cap61.99B
Price-Earnings ratio
15.12
Price-Earnings ratio15.12
Dividend yield
0.44%
Dividend yield0.44%
Average volume
1.22M
Average volume1.22M
High today
$608.97
High today$608.97
Low today
$584.41
Low today$584.41
Open price
$602.00
Open price$602.00
Volume
1.03M
Volume1.03M
52 Week high
$1,024.36
52 Week high$1,024.36
52 Week low
$476.49
52 Week low$476.49

REGN News

Simply Wall St 3h
Regeneron Pharmaceuticals: Valuation in Focus Following Breakthrough Pipeline Results and Expanded Drug Approvals

Regeneron Pharmaceuticals (REGN) has drawn renewed attention after reporting multiple pipeline milestones, including positive late-stage trial results for its o...

Regeneron Pharmaceuticals: Valuation in Focus Following Breakthrough Pipeline Results and Expanded Drug Approvals
Nasdaq 5h
Benjamin Graham Detailed Fundamental Analysis - REGN

Below is Validea's guru fundamental report for REGENERON PHARMACEUTICALS INC (REGN). Of the 22 guru strategies we follow, REGN rates highest using our Value Inv...

Benjamin Graham Detailed Fundamental Analysis - REGN
Simply Wall St 2d
Why Regeneron Is Up 6.4% After FDA Expansion and Positive Late-Stage Trial Results

In late September 2025, Regeneron Pharmaceuticals announced a series of major clinical and regulatory achievements, including expanded US FDA approval of Evkeez...

Why Regeneron Is Up 6.4% After FDA Expansion and Positive Late-Stage Trial Results

Analyst ratings

79%

of 28 ratings
Buy
78.6%
Hold
17.9%
Sell
3.6%

More REGN News

Simply Wall St 4d
Does Regeneron’s 8% Weekly Surge Signal a Shift After New FDA Drug Approval?

If you have found yourself wondering what to do with Regeneron Pharmaceuticals right now, you are not alone. This stock has managed to keep investors on their t...

Does Regeneron’s 8% Weekly Surge Signal a Shift After New FDA Drug Approval?
Nasdaq 5d
Formycon Reaches Settlement With Regeneron Over U.S. Eylea Biosimilar Patent Disputes

(RTTNews) - Formycon AG (FYB.DE), in collaboration with its license partners Klinge Biopharma GmbH and Valorum Biologics, has reached a settlement and entered i...

Formycon Reaches Settlement With Regeneron Over U.S. Eylea Biosimilar Patent Disputes

People also own

Based on the portfolios of people who own REGN. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.